| Characteristic | Intervention(s) and comparator(s) | Specific adverse events [description] | Specific adverse events [N] | Specific adverse events [%] |
| Ludvik 2002 | I1: sweet potato (Caiapo) tablets 2 g | ‐ | ‐ | ‐ |
| I2: sweet potato (Caiapo) tablets 4 g | ‐ | ‐ | ‐ | |
| C: placebo | ‐ | ‐ | ‐ | |
| Ludvik 2004 | I: sweet potato (Caiapo) tablets 4 g | ‐ | ‐ | ‐ |
| C: placebo | ‐ | ‐ | ‐ | |
| Ludvik 2008 | I: sweet potato (Caiapo) tablets 4 g | ‐ | ‐ | ‐ |
| C: placebo | ‐ | ‐ | ‐ | |
|
Footnotes "‐" denotes not reported C: comparator; I: intervention | ||||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.